EssilorLuxottica Wins 'Golden Key – China Action for SDGs' Award for Youth Vision Health Initiative

Shanghai, January 18, 2021 /PRNewswire/ -- Essilor was awarded the Excellence Award of “Golden Key – China Actions for SDGs” for its initiative “Engaging Diverse Partners to Safeguard Adolescent Vision Health.” This recognition underscores Essilor’s commitment to fulfilling its corporate mission of “Improving Vision, Improving Lives.”、Continuously Committed to Promoting Innovation and Sustainable Development in ChinaFieldAnother high level of recognition obtained.

“Golden Key – China’s Actions Toward the SDGs,” hosted by the Sustainable Economy Herald, aims to identify and shape benchmarks for China’s actions toward the Sustainable Development Goals (SDGs), and to tell and share stories and experiences of China’s sustainable development initiatives. The evaluation of the Golden Key Awards is conducted by representatives from renowned enterprises and international organizationsofComposed of experts with extensive leadership experience in the fields of corporate social responsibility and sustainable development. A total of 122 initiatives from 92 companies competed fiercely, undergoing rigorous evaluation through public online voting, on-site roadshow reviews, and expert voting on action video shorts, ultimately determining the winners in each category.

Mr. Dumanoy, Global Chief Mission Officer of EssilorLuxottica Group and President of Essilor Group Greater China, stated: “Possessing GoodGood vision is a fundamental right for everyone and a crucial prerequisite for the United Nations to achieve its 2030 Sustainable Development Goals. The recognition from the ‘Golden Key’ affirms our long-standing commitment to the noble mission of “Improving Vision, Improving Lives.” As a mission-driven company, Essilor will continue to promote sustainability, support the UN 2030 Agenda for Sustainable Development with innovative solutions, and work towards the ambitious vision of “eliminating poor vision within one generation.”

This award affirms EssilorForThree Innovative Measures to Address the Severe Issue of Adolescent Myopia: First, Innovation in Education and Awareness. Essilor supports the independent knowledge platform, Zhi Shi Ju.^TM Collaborate with Tencent to build a public-oriented eye health education knowledge system; jointly release with the National Institute of Education Sciences in ChinaPrefaceThe 3D pop-up book Our Eyes: Popular Science Education on Children's Vision Health applies innovative approaches to health education, fostering eye-care awareness among children and adolescents.

Second, jointly establishing industry standards. Essilor, in collaboration with the Optometry Group of the Ophthalmology Branch of the Chinese Medical Association and industry experts, jointly released the White Paper on Myopia Management Guidelines to guide proper clinical myopia management and help patients protect their eyes scientifically.

Third, providing innovative technologies and solutions. Essilor recently launched its groundbreaking myopia control solution in China – the Stellest® lenses. According to the results of a two-year clinical trial conducted by Wenzhou Medical University, while providing clear vision and comfortable wear, for children who wear Stellest® lenses for more than 12 hours per day, compared to Essilor single-vision lenses, Stellest® lenses can effectively slow down the progression of myopia by an average of 67%*.

Innovation is also reflected in helping adolescents through sustainable business models and interactive charitable initiatives. Essilor and Luxottica, in partnership with the Youai Charity Foundation, jointly launched the “Helping Plateau Children See the Future” public welfare campaign, leveraging their social media platforms and approximately 60 LensCrafters and Bolon eyewear storesStore PlanningRaise funds to helpZhu WanOver [number] students in Chengduo County, Yushu, Qinghai, received free vision screenings.

Meanwhile, Essilor helps populations with uncorrected vision due to lack of awareness or limited resources through its inclusive business initiative “2.5 New Vision Generation” and the charitable organization Essilor Vision Foundation. “2.5 New Vision Generation” is committed to strengthening infrastructure by establishing a multi-tiered professional optometric service network at the county, township, and village levels, providing affordable professional fitting services to people in areas with inadequate optometric care, and raising awareness of eye health. To date, it has cultivated nearly6000Dear Eye-Care Partners and Ambassadors,We are able to deliver sustainable optometric services to 75 million people. The Essilor Vision Foundation is committed to improving the visual health of adolescents in economically underdeveloped regions. By implementing vision health promotion programs, we provide free eye examinations for children and complimentary eyeglasses for those in need, along with training on eye-care knowledge. This ensures that children can not only see the blackboard clearly but also enjoy their fundamental right to continue pursuing education. To date, the Foundation’s initiatives have provided free vision screening to over 2.5 million students, advancing the United Nations Sustainable Development Goals through inclusive access to optometric care.

* Data Source:Two-year results of a prospective, randomized, double-blind, controlled clinical trial on myopia prevention and control initiated in 2018 by the Eye Hospital of Wenzhou Medical University (Chinese Clinical Trial Registry No. ChiCTR1800017683). In this study, 104 myopic children were randomly assigned to two groups: one wearing Stellest lenses (54 participants, study group) and the other wearing single-vision lenses (50 participants, control group). The reported 67% efficacy rate was derived from data on 32 children who wore Stellest lenses for more than 12 hours per day over two consecutive years, calculated using the formula: [(myopia progression in the control group (D) − myopia progression in the study group (D)) / myopia progression in the control group (D)] × 100%. All lenses used in this clinical trial were supplied by our company.